Cargando…
Comparison of Endostar continuous versus intermittent intravenous infusion in combination with first‐line chemotherapy in patients with advanced non‐small cell lung cancer
BACKGROUND: Intravenous infusion of Endostar for three to four hours per day for 14 days reduces patient compliance and affects quality of life. Continuous intravenous infusion (CI) represents a novel method of administration; however, it is unclear whether it is effective and safe when compared to...
Autores principales: | Cheng, Yuan, Nie, Ligong, Liu, Ying, Jin, Zhe, Wang, Xi, Hu, Zhanwei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons Australia, Ltd
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6610280/ https://www.ncbi.nlm.nih.gov/pubmed/31161695 http://dx.doi.org/10.1111/1759-7714.13106 |
Ejemplares similares
-
Endostar continuous versus intermittent intravenous infusion combined with chemotherapy for advanced NSCLC: a systematic review and meta-analysis including non-randomized studies
por: Wang, Bo, et al.
Publicado: (2020) -
Therapy with teicoplanin in the ICU: continuous intravenous infusion or intermittent intravenous administration?
por: Nardi, E, et al.
Publicado: (2008) -
Recombined humanized endostatin (Endostar) intravenous infusion in the treatment of refractory nasopharyngeal carcinoma: Three case reports
por: Chen, Chen, et al.
Publicado: (2019) -
Continuous Vancomycin Infusion versus Intermittent Infusion in Critically Ill Patients
por: Maluangnon, Chailat, et al.
Publicado: (2022) -
Meropenem administration by intermittent infusion versus continuous infusion for the treatment of nosocomial pneumonia
por: Lorente, L, et al.
Publicado: (2005)